A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,598,720 shares of XERS stock, worth $4.89 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,598,720
Previous 1,351,640 18.28%
Holding current value
$4.89 Million
Previous $3.04 Million 49.82%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.06 - $2.96 $508,984 - $731,356
247,080 Added 18.28%
1,598,720 $4.56 Million
Q2 2024

Aug 09, 2024

BUY
$1.7 - $2.45 $581,910 - $838,635
342,300 Added 33.91%
1,351,640 $3.04 Million
Q1 2024

May 13, 2024

SELL
$2.04 - $3.22 $759,492 - $1.2 Million
-372,300 Reduced 26.95%
1,009,340 $2.23 Million
Q4 2023

Feb 13, 2024

BUY
$1.47 - $2.36 $528,612 - $848,656
359,600 Added 35.18%
1,381,640 $3.25 Million
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $294,022 - $439,400
163,346 Added 19.02%
1,022,040 $1.9 Million
Q2 2023

Aug 11, 2023

BUY
$1.82 - $2.98 $463,736 - $759,304
254,800 Added 42.19%
858,694 $2.25 Million
Q1 2023

May 12, 2023

BUY
$1.03 - $1.63 $108,562 - $171,802
105,400 Added 21.14%
603,894 $984,000
Q4 2022

Feb 13, 2023

SELL
$1.14 - $1.65 $58,367 - $84,480
-51,200 Reduced 9.31%
498,494 $663,000
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $128,780 - $181,420
-94,000 Reduced 14.6%
549,694 $858,000
Q2 2022

Aug 12, 2022

SELL
$1.48 - $2.64 $72,964 - $130,152
-49,300 Reduced 7.11%
643,694 $991,000
Q1 2022

May 13, 2022

SELL
$2.0 - $2.87 $374,400 - $537,264
-187,200 Reduced 21.27%
692,994 $1.77 Million
Q4 2021

Feb 11, 2022

BUY
$1.8 - $2.93 $1.58 Million - $2.58 Million
880,194 New
880,194 $2.58 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $416M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.